Advertisement
Research ArticlePulmonology Free access | 10.1172/JCI32526
1Department of Pathology, 2Department of Medicine and Lung Biology Center, Pulmonary Division, 3Department of Surgery, and 4Department of Epidemiology and Biostatistics, Center for Bioinformatics and Molecular Biostatistics, UCSF, San Francisco, California, USA.
Address correspondence to: Stephen L. Nishimura, San Francisco General Hospital, Building 3, Room 211, 1001 Potrero Avenue, San Francisco, California 94110, USA. Phone: (415) 206-5906; Fax: (415) 206-5988; E-mail: stephen.nishimura@ucsf.edu.
Find articles by Araya, J. in: JCI | PubMed | Google Scholar
1Department of Pathology, 2Department of Medicine and Lung Biology Center, Pulmonary Division, 3Department of Surgery, and 4Department of Epidemiology and Biostatistics, Center for Bioinformatics and Molecular Biostatistics, UCSF, San Francisco, California, USA.
Address correspondence to: Stephen L. Nishimura, San Francisco General Hospital, Building 3, Room 211, 1001 Potrero Avenue, San Francisco, California 94110, USA. Phone: (415) 206-5906; Fax: (415) 206-5988; E-mail: stephen.nishimura@ucsf.edu.
Find articles by Cambier, S. in: JCI | PubMed | Google Scholar
1Department of Pathology, 2Department of Medicine and Lung Biology Center, Pulmonary Division, 3Department of Surgery, and 4Department of Epidemiology and Biostatistics, Center for Bioinformatics and Molecular Biostatistics, UCSF, San Francisco, California, USA.
Address correspondence to: Stephen L. Nishimura, San Francisco General Hospital, Building 3, Room 211, 1001 Potrero Avenue, San Francisco, California 94110, USA. Phone: (415) 206-5906; Fax: (415) 206-5988; E-mail: stephen.nishimura@ucsf.edu.
Find articles by Markovics, J. in: JCI | PubMed | Google Scholar
1Department of Pathology, 2Department of Medicine and Lung Biology Center, Pulmonary Division, 3Department of Surgery, and 4Department of Epidemiology and Biostatistics, Center for Bioinformatics and Molecular Biostatistics, UCSF, San Francisco, California, USA.
Address correspondence to: Stephen L. Nishimura, San Francisco General Hospital, Building 3, Room 211, 1001 Potrero Avenue, San Francisco, California 94110, USA. Phone: (415) 206-5906; Fax: (415) 206-5988; E-mail: stephen.nishimura@ucsf.edu.
Find articles by Wolters, P. in: JCI | PubMed | Google Scholar
1Department of Pathology, 2Department of Medicine and Lung Biology Center, Pulmonary Division, 3Department of Surgery, and 4Department of Epidemiology and Biostatistics, Center for Bioinformatics and Molecular Biostatistics, UCSF, San Francisco, California, USA.
Address correspondence to: Stephen L. Nishimura, San Francisco General Hospital, Building 3, Room 211, 1001 Potrero Avenue, San Francisco, California 94110, USA. Phone: (415) 206-5906; Fax: (415) 206-5988; E-mail: stephen.nishimura@ucsf.edu.
Find articles by Jablons, D. in: JCI | PubMed | Google Scholar
1Department of Pathology, 2Department of Medicine and Lung Biology Center, Pulmonary Division, 3Department of Surgery, and 4Department of Epidemiology and Biostatistics, Center for Bioinformatics and Molecular Biostatistics, UCSF, San Francisco, California, USA.
Address correspondence to: Stephen L. Nishimura, San Francisco General Hospital, Building 3, Room 211, 1001 Potrero Avenue, San Francisco, California 94110, USA. Phone: (415) 206-5906; Fax: (415) 206-5988; E-mail: stephen.nishimura@ucsf.edu.
Find articles by Hill, A. in: JCI | PubMed | Google Scholar
1Department of Pathology, 2Department of Medicine and Lung Biology Center, Pulmonary Division, 3Department of Surgery, and 4Department of Epidemiology and Biostatistics, Center for Bioinformatics and Molecular Biostatistics, UCSF, San Francisco, California, USA.
Address correspondence to: Stephen L. Nishimura, San Francisco General Hospital, Building 3, Room 211, 1001 Potrero Avenue, San Francisco, California 94110, USA. Phone: (415) 206-5906; Fax: (415) 206-5988; E-mail: stephen.nishimura@ucsf.edu.
Find articles by Finkbeiner, W. in: JCI | PubMed | Google Scholar
1Department of Pathology, 2Department of Medicine and Lung Biology Center, Pulmonary Division, 3Department of Surgery, and 4Department of Epidemiology and Biostatistics, Center for Bioinformatics and Molecular Biostatistics, UCSF, San Francisco, California, USA.
Address correspondence to: Stephen L. Nishimura, San Francisco General Hospital, Building 3, Room 211, 1001 Potrero Avenue, San Francisco, California 94110, USA. Phone: (415) 206-5906; Fax: (415) 206-5988; E-mail: stephen.nishimura@ucsf.edu.
Find articles by Jones, K. in: JCI | PubMed | Google Scholar
1Department of Pathology, 2Department of Medicine and Lung Biology Center, Pulmonary Division, 3Department of Surgery, and 4Department of Epidemiology and Biostatistics, Center for Bioinformatics and Molecular Biostatistics, UCSF, San Francisco, California, USA.
Address correspondence to: Stephen L. Nishimura, San Francisco General Hospital, Building 3, Room 211, 1001 Potrero Avenue, San Francisco, California 94110, USA. Phone: (415) 206-5906; Fax: (415) 206-5988; E-mail: stephen.nishimura@ucsf.edu.
Find articles by Broaddus, V. in: JCI | PubMed | Google Scholar
1Department of Pathology, 2Department of Medicine and Lung Biology Center, Pulmonary Division, 3Department of Surgery, and 4Department of Epidemiology and Biostatistics, Center for Bioinformatics and Molecular Biostatistics, UCSF, San Francisco, California, USA.
Address correspondence to: Stephen L. Nishimura, San Francisco General Hospital, Building 3, Room 211, 1001 Potrero Avenue, San Francisco, California 94110, USA. Phone: (415) 206-5906; Fax: (415) 206-5988; E-mail: stephen.nishimura@ucsf.edu.
Find articles by Sheppard, D. in: JCI | PubMed | Google Scholar
1Department of Pathology, 2Department of Medicine and Lung Biology Center, Pulmonary Division, 3Department of Surgery, and 4Department of Epidemiology and Biostatistics, Center for Bioinformatics and Molecular Biostatistics, UCSF, San Francisco, California, USA.
Address correspondence to: Stephen L. Nishimura, San Francisco General Hospital, Building 3, Room 211, 1001 Potrero Avenue, San Francisco, California 94110, USA. Phone: (415) 206-5906; Fax: (415) 206-5988; E-mail: stephen.nishimura@ucsf.edu.
Find articles by Barzcak, A. in: JCI | PubMed | Google Scholar
1Department of Pathology, 2Department of Medicine and Lung Biology Center, Pulmonary Division, 3Department of Surgery, and 4Department of Epidemiology and Biostatistics, Center for Bioinformatics and Molecular Biostatistics, UCSF, San Francisco, California, USA.
Address correspondence to: Stephen L. Nishimura, San Francisco General Hospital, Building 3, Room 211, 1001 Potrero Avenue, San Francisco, California 94110, USA. Phone: (415) 206-5906; Fax: (415) 206-5988; E-mail: stephen.nishimura@ucsf.edu.
Find articles by Xiao, Y. in: JCI | PubMed | Google Scholar
1Department of Pathology, 2Department of Medicine and Lung Biology Center, Pulmonary Division, 3Department of Surgery, and 4Department of Epidemiology and Biostatistics, Center for Bioinformatics and Molecular Biostatistics, UCSF, San Francisco, California, USA.
Address correspondence to: Stephen L. Nishimura, San Francisco General Hospital, Building 3, Room 211, 1001 Potrero Avenue, San Francisco, California 94110, USA. Phone: (415) 206-5906; Fax: (415) 206-5988; E-mail: stephen.nishimura@ucsf.edu.
Find articles by Erle, D. in: JCI | PubMed | Google Scholar
1Department of Pathology, 2Department of Medicine and Lung Biology Center, Pulmonary Division, 3Department of Surgery, and 4Department of Epidemiology and Biostatistics, Center for Bioinformatics and Molecular Biostatistics, UCSF, San Francisco, California, USA.
Address correspondence to: Stephen L. Nishimura, San Francisco General Hospital, Building 3, Room 211, 1001 Potrero Avenue, San Francisco, California 94110, USA. Phone: (415) 206-5906; Fax: (415) 206-5988; E-mail: stephen.nishimura@ucsf.edu.
Find articles by Nishimura, S. in: JCI | PubMed | Google Scholar
Published October 25, 2007 - More info
Squamous metaplasia (SM) is common in smokers and is associated with airway obstruction in chronic obstructive pulmonary disease (COPD). A major mechanism of airway obstruction in COPD is thickening of the small airway walls. We asked whether SM actively contributes to airway wall thickening through alteration of epithelial-mesenchymal interactions in COPD. Using immunohistochemical staining, airway morphometry, and fibroblast culture of lung samples from COPD patients; genome-wide analysis of an in vitro model of SM; and in vitro modeling of human airway epithelial-mesenchymal interactions, we provide evidence that SM, through the increased secretion of IL-1β, induces a fibrotic response in adjacent airway fibroblasts. We identify a pivotal role for integrin-mediated TGF-β activation in amplifying SM and driving IL-1β–dependent profibrotic mesenchymal responses. Finally, we show that SM correlates with increased severity of COPD and that fibroblast expression of the integrin αvβ8, which is the major mediator of airway fibroblast TGF-β activation, correlated with disease severity and small airway wall thickening in COPD. Our findings have identified TGF-β as a potential therapeutic target for COPD.
Chronic obstructive pulmonary disease (COPD) is the fourth-leading cause of death worldwide and affects up to 50% of long-term smokers (1, 2). The major histopathologic correlates of airway obstruction in COPD are loss of alveolar walls and narrowing of the small airways (3). The relative contribution of each of these pathologic features to airway obstruction is not completely understood (4). However, recently, airway wall thickening has been identified as a major independent predictor of the severity of physiologic airway obstruction in COPD patients stratified by the criteria established by the Global Initiative for Obstructive Lung Disease (GOLD; http://www.goldcopd.com/), suggesting that airway-wall fibrosis contributes to airway obstruction (5). COPD is caused by the noxious effects of tobacco smoke, which leads to airway epithelial injury and the induction of changes such as squamous metaplasia (SM), the reversible replacement of the normal columnar epithelium by squamous epithelium (6). In 1978, Cosio et al. noted that SM correlated with the severity of airway obstruction, suggesting that SM and airway obstruction may be linked (7).
Changes in airway epithelium have the potential to alter the finely balanced reciprocal interactions between the epithelium and mesenchyme that influences cellular differentiation, the so-called epithelial-mesenchymal trophic unit (8, 9). Thus, SM developing in response to pathologic stimuli may alter normal homeostatic autocrine and paracrine interactions between the epithelium and the surrounding fibroblast sheath. Recently, we provided evidence for a homeostatic role for integrin-mediated TGF-β activation in a human model of the epithelial-mesenchymal trophic unit (10). In this model, fibroblastic integrin αvβ8-mediated TGF-β activation was found to regulate the fibrogenic phenotype as well as synthesis and secretion of HGF, which influences the proliferation of adjacent airway epithelial cells (10).
TGF-β is a major fibrogenic cytokine regulating both extracellular matrix deposition and immune homeostasis that may link SM and airway obstruction. TGF-β is a major factor in driving SM of airway epithelial cells in vitro (11). Increased TGF-β can be found in the small airway epithelium of COPD patients, and its levels correlate with the severity of obstruction (12, 13). Polymorphisms in the TGF-β1 promoter have been shown to increase susceptibility to COPD (14). Adenoviral transfer of TGF-β1 to murine lung has been shown to increase fibroblast accumulation around airways, and airway epithelial transgenic expression of TGF-β causes peribronchiolar fibrosis, an effect that is reversible (15, 16). These results implicate TGF-β–mediated airway remodeling as a potential therapeutic target.
TGF-β is ubiquitously expressed in 3 isoforms in all mammalian cell types and tissues but is found almost entirely in a latent form, consisting of the noncovalent interactions between the latency-associated peptide (LAP) of TGF-β and the mature peptide of TGF-β and covalent interactions with latent TGF-β–binding proteins (17, 18). Thus, a major point of regulation of TGF-β function is through its activation, which occurs by 2 general mechanisms, those that alter the conformation of LAP and those that result in the proteolytic cleavage of LAP (17, 19–21). The integrins αvβ6 and αvβ8, heterodimers that have the αn integrin subunit in common, can each bind to and activate latent TGF-β (20, 21) and together may account for the majority of TGF-β1 activation during murine development (22). In the case of αvβ6, interaction with latent TGF-β results in conformational alteration of LAP, allowing cell-associated active TGF-β to interact with TGF-β receptors on immediately adjacent cells (21). In the case of αvβ8, binding of latent TGF-β results in the metalloproteolytic cleavage of LAP and release of active TGF-β from the cell surface, where it can then act as an autocrine or paracrine factor (20). Both αvβ6 and αvβ8 are expressed by human airway epithelial cells; αvβ8 (but not αvβ6) is expressed by human airway fibroblasts.
Of the many cytokines that have been implicated in the pathogenesis of COPD, IL-1β, a major proinflammatory cytokine, is of particular interest (23). IL-1β has been found in higher levels in alveolar macrophages from smokers and in cigarette smoke–treated airway epithelial cells from COPD patients (24). Transgenic overexpression of IL-1β in airway epithelial cells leads to airway inflammation, emphysema, and airway-wall thickening (25).
Here we report a link between SM of airway epithelium and airway-wall thickening through a mechanism involving increased secretion of IL-1β and increased integrin-mediated activation of TGF-β.
SM in the small airways of COPD patients. Involucrin is a component of the cornified envelope of stratified squamous epithelium and is a marker of SM in the airway epithelium (26). In the human small airways, involucrin staining was found in superficial metaplastic airway epithelial cells in areas of cuboidal airway epithelium devoid of cilia as well as in areas of morphologically obvious SM, confirming involucrin as a robust marker for SM (Figure 1A). Involucrin staining intensity in the small airway epithelium was significantly increased in patients with GOLD stages 2 and 3 COPD compared with normal controls (Figure 1B).
SM correlates with increased GOLD stage of COPD in human lung samples, and SM can be induced during in vitro culture. (A) Involucrin (IVL), a marker of epidermal differentiation (26), stains small airway SM. Shown is a photomicrograph of metaplastic squamous cells (arrows) of a small airway from a COPD patient stained with anti-IVL. Scale bar: 50 μm. (B) IVL-staining intensity of lung samples from normal versus COPD patients stratified according to GOLD (www.goldcopd.com), and assessed by grading digital images (0–3 scale) with 0 being absent; grade 1, 0–10%; grade 2, 11–20%; and grade 3, >20% cytoplasmic staining. *P < 0.05. (C) Photomicrographs of P0 compared with P3 human bronchial epithelial cells. Upper panels are stained with the basal cell marker anti-p63 and lower panels with anti-IVL. Scale bar: 50 μm. (D) Western blotting of 40 μg of P0 or P3 human bronchial epithelial cells total cell lysates for p63 and IVL. (E) Propidium iodide (PI) staining and flow cytometry of serially passaged human bronchial epithelial cells of a representative experiment (n = 3) showing the relative proportion of cells in the G0/G1, S, and G2/M phases of the cell cycle. (F) Relative proportion (± SEM) of human bronchial epithelial cells (n = 3) in G0/G1 compared with S and G2/M phases of the cell cycle during serial passage. *P < 0.01. (G) Senescence-associated β-gal (SA β-gal) staining of serially passaged human bronchial epithelial cells (n = 3). Shown is the percentage (± SEM) of SA β-gal–positive cells. *P < 0.01; **P < 0.001.
In vitro model of human airway epithelial squamous metaplasia. Human bronchial epithelial cells undergo SM during cell culture in the absence of retinoic acid (11). We found that in 2D cultures, in the low retinoic acid concentrations of our commercial airway epithelial medium preparation (0.3 nM; ref. 27), human bronchial epithelial cells phenotypically changed during serial passage from small poorly spread round cells to large and flattened squamous-like cells (Figure 1C). At the initial passage (P0), we determined that the cultures consisted mostly of basal cells, the progenitor cells of the human airway, because more than 95% of the cells expressed p63 (Figure 1C), a marker of basal cell differentiation (28). By the third passage (P3), the human bronchial epithelial cells displayed reduced p63 and strong involucrin staining (Figure 1C) typical of metaplastic squamous epithelial cells (29). Western blotting of human bronchial epithelial cell lysates confirmed the acquisition of a squamous cell phenotype during serial passage, since high p63 and low involucrin expression were found in P0 human bronchial epithelial cell lysates and low p63 and high involucrin expression were found in P3 human bronchial epithelial cell lysates (Figure 1D). These data are in agreement with previous studies using similar media, demonstrating that the primary cell in 2D tracheobronchial culture is initially the basal cell, which changes to an SM-like cell during serial passage (29).
SM in COPD patients is not only characterized by the onset of epidermal differentiation but is also a hyperproliferative state (30). Thus, we characterized cell proliferation and senescence of serially passaged human bronchial epithelial cells. The percentage of actively proliferating cells in the S and G2/M phases of the cell cycle remained high (~30%) and did not significantly change during the P0 to P3 culture period, but by P6, proliferation had markedly decreased due to an accumulation of cells in the G0/G1 phase of the cell cycle (Figure 1, E and F). The fraction of senescent cells did not significantly change between P0 and P3 but increased significantly in subsequent passages (Figure 1G). We conclude that at P3, human bronchial epithelial cells in 2D culture approximate the hyperproliferative state of SM in vivo and avoid the in vitro phenomenon of replicative senescence.
Global analysis of gene expression during SM reveals induction of the proinflammatory mediators IL-1α and IL-1β. We analyzed the changes in human bronchial epithelial cell gene expression occurring during the culture period from P0 to P3 using high-density oligonucleotide microarrays. In the transition from P0 to P3, there were 278 genes induced and 225 genes repressed (503 total) that reached statistical significance (http://www.ncbi.nlm.nih.gov/geo/, Geo accession number: GSE7557). Gene ontology analysis of the statistically significant induced genes revealed enrichment of a number of functional categories, including cell motility, cytoskeletal assembly, ectodermal development, IL-1 receptor binding, cell proliferation, and cell adhesion (Supplemental Table 1; supplemental material available online with this article; doi:10.1172/JCI32526DS1). Statistically significant repressed genes included only the immune response group (Supplemental Table 2).
Of the 503 statistically significant differentially expressed genes, 93 and 62 were at least 2-fold induced or repressed, respectively. Most notably, IL-1β (13.4-fold), IL-1α (9.7-fold), and the TGF-β–responsive gene, plasminogen-activator inhibitor (SERPINE1, 6.9-fold), were the first, third, and sixth most highly induced genes, respectively (Table 1). Other genes known to be induced by TGF-β in epithelial cells that were also differentially expressed at least 2-fold in P3 airway epithelial cultures (see Table 1 and http://www.ncbi.nlm.nih.gov/geo/, Geo accession number: GSE7557) included the integrin β6 (ITGB6) (31), the T cell differentiation protein (MAL) (32), the TGF-β inducible gene (BIGH3) (33), and laminin A3 (LAMA3) (32), suggesting increased autocrine TGF-β signaling during serial passage. In addition, a number of genes involved in epidermal differentiation (KRT6B, S100A8, GJ1A, IVL, DSC2, KRT14, DESC1, A2ML) were highly induced during serial passage; 3 of these (KRT6, IVL, and KRT14) have been reported to label actively proliferating suprabasal cells in the squamous mucosa or in SM (34–37) (Table 1).
Twenty-five most highly induced genes during human bronchial epithelial cells’ serial passage
Immunocytochemistry confirmed the suprabasal differentiation state of P3 human bronchial epithelial cells since 80%, 61%, and 88% of cells expressed keratin 6, keratin 14, and involucrin, respectively (Supplemental Figure 1). A high percentage (42%) of the involucrin-stained P3 cells were actively proliferating, since they were in the S or G2/M phase of the cell cycle (Supplemental Figure 2). Finally, 76%, 67%, and 90% of IL-1β–positive P3 human bronchial epithelial cells coexpressed keratin 6, keratin 14, and involucrin, respectively (Supplemental Figure 1). These data demonstrate that P3 human bronchial epithelial cells represent actively proliferating IL-1β–producing suprabasal squamous cells.
IL-1α and IL-1β are functionally redundant and bind to the same IL-1 receptor and endogenous soluble receptor antagonist (IL-1RA) but differ in that IL-1β is secreted whereas IL-1α exists in both a membrane-bound and cleaved (secreted) form. Increased levels of IL-1α and IL-1β in P3 human bronchial epithelial cells were confirmed by RT-PCR (Figure 2A), cytokine antibody array (Figure 2B), and ELISA (Figure 2C). The increase in IL-1β in the supernatant of P3 airway epithelial supernatants was approximately 30 pg/ml. This level is in 4-fold greater excess than found in synovial fluid from patients with rheumatoid arthritis (38). Finally, to confirm the physiological relevance of our 2D system, we used air-liquid interface culture conditions. Thus, human bronchial epithelial cells were grown on top of filters and only the basal surface of the cells was allowed to remain in contact with the medium, which simulates the anatomic arrangement in the airway in vivo (39). Human bronchial epithelial cells (P0) grown in air-liquid interface conditions for 21 days using SM-promoting medium conditions adopted a squamous metaplastic phenotype and expressed involucrin in the basal and suprabasal cells (Figure 2D) and expressed IL-1β (Figure 2E). Air-liquid interface cultures grown in airway-differentiating medium adopted a pseudostratified ciliated columnar phenotype and expressed neither involucrin nor IL-1β (Figure 2D and Figure 2E).
IL-1α and IL-1β are induced during SM. (A) RT-PCR of total RNA from P0 to P3 human bronchial epithelial cells grown in 2D culture, using primers to IL-1α and IL-1β and β-actin, as a control. Shown is a representative experiment from paired samples from 3 different patients with the same results. (B) Antibody cytokine array showing increased IL-1β and -α in conditioned medium taken from P0 or P3 human bronchial epithelial cells. Upper and lower panels are duplicates. Shown is a representative experiment from 3 separate patients showing similar results. (C) IL-1β ELISA assay showing increased IL-1β in conditioned medium from P0 compared with P3 human bronchial epithelial cells. **P < 0.001. (D) Involucrin immunostaining of P0 human bronchial epithelial cells grown in air-liquid interface culture for 21 days. Human bronchial epithelial cells grown in 2% Ultraser G (Invitrogen) produced differentiated pseudostratified ciliated columnar epithelium (NL, upper panel). When grown in BEGM (Clonetics), the cells adopted a squamous metaplastic phenotype and expressed involucrin (SM, lower panel). Arrows indicate involucrin staining of basal and suprabasal squamous metaplastic epithelial cells. Scale bar: 20 μm. (E) RT-PCR of total RNA harvested from human bronchial epithelial cells grown in air-liquid interface for 3 days or 21 days in differentiating medium (USG) or SM medium (BEGM) using primers to IL-1β or β-actin as controls.
In vitro SM closely mimics metaplastic squamous epithelium in COPD in vivo. We characterized and confirmed the increased expression of IL-1β and the epidermal differentiation genes found using P0–P3 oligoarrays by immunohistochemical staining of tissue samples of human airway SM from COPD patients and compared the staining pattern with normal and wounded epidermis, squamous mucosa, and SM from a variety of mucosal sites. Antibodies to IL-1β stained basal, suprabasal, and superficial cells of metaplastic squamous airway epithelium (Figure 3A) but did not stain normal airway epithelium from COPD patients (Figure 3B). The staining was specific, as no staining was observed after preabsorption of the antibody with the immunogen (Figure 3C). Antibodies to involucrin and keratin 6 stained the superficial and suprabasal cells of the squamous metaplastic epithelium (Figure 3, E and G) but not normal epithelium (Figure 3, F and H). Keratin 14 immunolocalized to the basal and suprabasal cells of SM (Figure 3I) and stained only the basal cells of the normal airway (Figure 3J). The basal and suprabasal cells of SM stained intensely with antibodies to integrin β6 (Figure 3K) while the basal cells of the normal epithelium only lightly stained (Figure 3L); the opposite was true of integrin β8 (Figure 3, M and N). The basal and suprabasal cells of SM stained intensely with antibodies to the proliferation marker Ki-67 (Figure 3O) while fewer scattered basal cells of the normal airway stained (Figure 3P). The basal cell marker p63 (28) intensely stained basal cells and moderately labeled suprabasal cells of SM (Figure 3Q) while staining only basal cells of the normal airway (Figure 3R). A pattern of immunoreactivity similar to that seen in SM of the airways in COPD was seen in the squamous mucosa of the cervix, and in the epidermis at the edge of healing wounds (Supplemental Data and Supplemental Table 3). We conclude that P3 human bronchial epithelial cells in 2D culture closely approximate SM in the airway in COPD as well as in other mucosal sites.
IL-1β is coexpressed with integrins αvβ6 and αvβ8 in hyperproliferative suprabasal squamous metaplastic airway epithelium of COPD patients. Immunostaining of adjacent paraffin sections from an airway with a focus of SM (Sq. Met.: A, C, E, G, I, K, M, O, and Q) compared with relatively normal airway mucosa (B, D, F, H, J, L, N, P, and R) from a COPD patient using antibodies to (A and B) IL-1β; (C and D) IL-1β preabsorbed with the immunogenic peptide (control); (E and F) the suprabasal markers anti-involucrin; (G and H) anti–keratin 6; (I and J) anti–keratin 14; (K and L) the TGF-β activating integrins β6; (M and N) and β8; (O and P) the cell proliferation marker Ki-67; (Q and R) the basal cell marker p63. Arrows point to the basement membrane. Shown is a representative experiment of 3 showing similar results. Scale bar: 100 μm.
IL-1β released by squamous metaplastic epithelium increases αvβ8 integrin expression and αvβ8-mediated TGF-β activation in human airway fibroblasts. We hypothesized that IL-1β released by metaplastic squamous epithelial cells contributed to a profibrotic fibroblast phenotype by increasing fibroblast TGF-β activation, a largely integrin αvβ8–mediated process (10). Indeed, we found that αvβ8 integrin expression (Figure 4, A and B) and αvβ8 integrin–mediated TGF-β activation (Figure 4C) in human airway fibroblasts was increased by treatment either with recombinant IL-1β (data not shown) or by coculture with squamous metaplastic (P3) epithelial cells. Increased fibroblast β8 expression caused by coculture with squamous metaplastic epithelial cells was IL-1 dependent, since IL-1RA, a physiological inhibitor of both IL-1α and IL-1β, almost completely inhibited the increase in β8 expression (Figure 4D). The airway epithelial cells were the sole source of IL-1 in the coculture system because neither IL-1α nor IL-1β mRNA could be detected in normal airway fibroblasts by RT-PCR (data not shown).
Paracrine secretion of IL-1β by P3 human bronchial epithelial cells increases β8 expression and αvβ8-mediated TGF-β activation of adjacent airway fibroblasts in a coculture model of the epithelial-mesenchymal trophic unit. Normal adult airway fibroblasts were cultured alone (Mono) or cocultured (Co) with P3 human bronchial epithelial cells grown on filter inserts. (A) Total fibroblast RNA was harvested and RT-PCR performed using primers specific for β8 or β-actin, as a control. Shown is a representative experiment of 3 with similar results. No cDNA indicates a no template control. (B) Fibroblasts (n = 3) in mono- or coculture were stained with anti-β8 and analyzed by flow cytometry. Shown is mean fluorescence in arbitrary units. (C) Monocultured fibroblasts or fibroblasts after 48-hour coculture with P0 or P3 human bronchial epithelial cells (n = 6) were cocultured with TGF-β reporter cells in the presence of neutralizing anti-β8, or no antibody (none). Shown is fold increase in TGF-β activation relative to untreated fibroblasts in monoculture. (D) Airway fibroblasts (n = 3) were cocultured with P0 or P3 conditioned medium (CM) in the presence of no antagonist or different concentrations (5, 50, or 500 ng/ml) of IL-1RA, a naturally occurring soluble antagonist of IL-1α and IL-1β. The fibroblasts were stained with anti-β8 and analyzed using flow cytometry. Shown is the fold increase in β8 expression compared with matched airway fibroblasts grown without conditioned medium. **P < 0.001.
IL-1β released by squamous metaplastic epithelium causes an αvβ8- and TGF-β–dependent switch to a fibrogenic fibroblast phenotype. Increased ECM production and increased fibroblast contractility are hallmarks of fibrotic responses seen in airway wall thickening, and increased type I collagen (Col I) and increased SMA (αSMA) are key biochemical markers of that response. To assess the contribution of autocrine αvβ8–mediated TGF-β activation to the profibrotic fibroblast phenotype, we used siRNA to knock down β8 expression in airway fibroblasts. Treatment of normal airway fibroblasts with β8 siRNA significantly reduced β8 expression as assessed by RT-PCR (Figure 5A) and flow cytometry (Figure 5B) and completely inhibited αvβ8-mediated TGF-β activation (Figure 5C). These effects were specific to β8 siRNA since they were not seen with control siRNA (Figure 5, A–C). Neutralizing anti-β8 and β8 siRNA blocked only approximately 50% of the total TGF-β activation as determined using a TGF-β neutralizing antibody that inhibits the function of all 3 TGF-β isoforms (Figure 5C). Thus, the incomplete inhibition of TGF-β activation could be due to activation of TGF-β2 by an αvβ8-independent mechanism, since αvβ8 is only involved in the activation of TGF-β1 and -β3 (10, 20). Alternatively, the incomplete inhibition may be due to the relatively poor efficacy of the β8-neutralizing antibody and the incomplete silencing achieved with β8 siRNA (Figure 5A). Autocrine αvβ8-mediated activation of TGF-β influenced the myofibroblast phenotype, since treatment of airway fibroblasts with β8 siRNA reduced αSMA expression (Figure 5D) and Col I secretion (Figure 5E). Coculture of airway fibroblasts with P3 human bronchial epithelial cells led to an increase in Col I transcription and protein production by airway fibroblasts (Figure 5E). The increased production of collagen was IL-1β– and fibroblast β8–dependent because the increase in Col I expression induced by coculture with P3 human bronchial epithelial cells could almost be completely inhibited by treatment of cocultures with IL-1RA (Figure 5E) or by transfection of airway fibroblasts with β8 siRNA (Figure 5E).
Autocrine αvβ8-mediated TGF-β activation regulates the airway fibroblast contractile phenotype and collagen production. siRNA to β8 or a control siRNA were transfected into normal adult airway fibroblasts and 72 hours following transfection were analyzed. (A) RT-PCR using primers to β8 or β-actin as a control. Shown is a representative experiment of 4 showing similar results. (B) Flow cytometry using anti-β8. Shown is mean fluorescence (n = 4) in arbitrary units ± SEM. *P < 0.05. (C) The TGF-β reporter cell line, TMLC, in the presence of anti-β8 or isotype-matched control antibodies (n = 3). TGF-β activation is shown as relative to the total TGF-β activation seen in control antibody, control siRNA–treated cells. *P < 0.05, **P < 0.001. (D) Western blot (WB) using anti-αSMA or RT-PCR using primers to αSMA or β-actin as a control. Shown is a representative experiment of 3 showing similar results. (E) RT-PCR of fibroblasts cultured alone (monoculture) or in coculture treated with either a control antibody (control Ab) or IL-1RA using primers to Col I or β-actin as a control, or Western blot using anti–Col I. Shown is a representative experiment of 3 showing similar results.
IL-1β–dependent increase in αvβ8-mediated activation of TGF-β is MT1-MMP dependent. IL-1β, while increasing β8 expression, also has diverse functional effects, including increased transcription of membrane type I–MMP (MT1-MMP) (40) and TGF-β (41), either of which could independently increase the efficiency of β8 integrin–mediated TGF-β activation (20). Indeed, treatment of airway fibroblasts with IL-1β also increased MT1-MMP activity (not shown). To determine whether the IL-1β–dependent increase in fibroblast αvβ8–mediated TGF-β activation was due to increased β8 expression or to increased MT1-MMP activity, we overexpressed either β8 or MT1-MMP in airway fibroblasts. Transient β8 transfection significantly increased β8 integrin expression and αvβ8-mediated TGF-β activation (Figure 6, A and B) and did not affect MT1-MMP activity or expression (not shown). Conversely, overexpression of MT1-MMP, which increased MT1-MMP activity more than 100-fold (data not shown) had no effect on β8 expression (data not shown) or αvβ8-mediated TGF-β activation (Figure 6C). However, transfection of airway fibroblasts with MT1-MMP siRNA, which inhibited approximately 70% of MT1-MMP surface expression (Figure 6D) and activity (not shown), markedly inhibited αvβ8-mediated activation of TGF-β (Figure 6E). In contrast, treatment of airway fibroblasts with IL-1β did not increase TGF-β transcription (ratio of TGF-β to β-actin transcript: nontreated, 0.97 ± 0.11; IL-1β treated, 0.87 ± 0.16, n = 3) or secretion (TGF-β activity as measured by TGF-β bioassay: control, 1269 ± 131; IL-1β treated, 1152 ± 129, n = 4). These results demonstrate that the endogenous level of functionally active MT1-MMP present in airway fibroblasts is sufficient to support αvβ8-mediated activation of TGF-β and that the IL-1β–induced increases in TGF-β activation are due to increased β8 expression and not increased activity of MT1-MMP or expression of TGF-β.
Increased αvβ8-mediated activation of TGF-β in airway fibroblasts is mediated through increased β8 expression and not increased MT1-MMP activity. (A) Airway fibroblasts (n = 4) were transiently transfected with a control vector (pcDNA1) or β8 expression construct and assessed for β8 expression by flow cytometry using anti-β8. ***P < 0.001. (B) Control or β8 transfectants (n = 3) were cocultured with TGF-β reporter cells in the presence or absence of neutralizing anti-β8. Shown is TGF-β activation relative to mock-transfected control. *P < 0.05. (C) Airway fibroblasts transfected with a control or MT1-MMP expression vector were cocultured with TGF-β reporter cells in the presence or absence of neutralizing anti-β8 or the metalloprotease inhibitor GM6001. TGF-β activation was determined using a pan–TGF-β blocking antibody. (D) Airway fibroblasts were transfected with control siRNA or MT1-MMP siRNA and assessed for MT1-MMP expression by RT-PCR using primers to MT1-MMP or β-actin as a control at 24, 48, or 72 hours (upper panel). In the lower panel, transfected airway fibroblasts 72 hours after transfection were surface labeled. Cell lysates were immunoprecipitated with anti–MT1-MMP. Shown is a representative experiment of 3, showing similar results. (E) Airway fibroblasts (n = 3) transfected with control or MT1-MMP siRNA were cocultured with TGF-β reporter cells in the presence or absence of anti–TGF-β, anti-β8, a pan-metalloprotease inhibitor, GM6001, a TGF-β1 RGD peptide (20), or isotype-matched control. The percentage of the total TGF-β activation (± SEM) was defined using an anti–TGF-β neutralizing antibody. *P < 0.05; **P < 0.001.
Increased TGF-β activation during serial passage of airway epithelial cells. We next addressed the role of integrin-mediated activation of TGF-β in driving SM. The TGF-β–activating integrin αvβ6 showed a dramatic increase in mRNA and surface expression during serial passage of airway epithelial cells. At P0, airway epithelial cells expressed little αvβ6. By P1, high levels of αvβ6 were detected, which persisted throughout later passages (Figure 7A). The other TGF-β–activating integrin expressed by airway epithelial cells, αvβ8, showed high expression in P0 cells and demonstrated a slight decrease during serial passage (Figure 7A). Approximately 50% of TGF-β activation by airway epithelial cells from P0 to P3 was accounted for by the αvβ6 integrin, with the αvβ8 integrin contributing little to the total TGF-β activation (Figure 7B). This is consistent with our previous observations that airway epithelial cells under these culture conditions require stimulation to support full αvβ8-mediated activation of TGF-β (10). Anti-αvβ3 and anti-αvβ5 integrin antibodies showed no effects on TGF-β activation (data not shown).
αvβ6-mediated TGF-β activation forms a self-amplifying loop of increasing TGF-β activation in human bronchial epithelial cells, which drives SM. Normal human bronchial epithelial cells in 2D culture (n = 3) were assessed during serial passage (P0–P3) for integrin αvβ6 and αvβ8 expression by (A, upper panel) RT-PCR using primers specific for β8, β6, or β-actin, as a control or (A, lower panel) flow cytometry using no antibody, anti-β6, or anti-β8 (± SEM). (B) Human bronchial epithelial cells (n = 5) were tested for changes in integrin-mediated TGF-β activation during serial passage using TGF-β bioassay (± SEM). TGF-β activation was determined using pan–anti–TGF-β. (C) P2 human bronchial epithelial cells in 2D culture were treated for 4 days with no primary antibody, neutralizing anti–TGF-β, anti-β8, or anti-β6. RT-PCR was performed using primers to β8, β6, or β-actin, as a control (n = 5). Densitometry values were normalized to β-actin, and the results were expressed as fold decrease (± SE) relative to control antibody–treated cells where a value of 1 represents no change from control antibody–treated cells. *P < 0.05 (D) P2 human bronchial epithelial cells in 2D culture were treated with control antibody or neutralizing anti-β6, and total RNA was harvested and assessed for the EDC genes (42, 43), involucrin (IVL), desmocollin-2 (DSC2), small proline rich protein-1A (SPRR1A), -1B (SPRR1B) (n = 3), -3 (SPRR3), or S100A7 (n = 2) using real-time PCR. Shown is the fold reduction (log 10) in expression of EDC genes after treatment with anti-β6 compared with control antibody–treated samples.
Airway epithelial β6 expression has previously been reported to be increased by exogenous active TGF-β (31). Here, increased β6 expression was partially mediated by autocrine αvβ6–mediated activation of TGF-β, since treatment of airway epithelial cells (P2) with neutralizing anti-β6 or TGF-β antibodies caused a decrease in β6 mRNA (Figure 7C). This effect was specific to αvβ6-mediated activation of TGF-β, since anti-β8 had no effect (Figure 7C). These results suggest that the integrin αvβ6 provides a self-amplifying autocrine loop of TGF-β activation during the metaplastic process.
Role of autocrine and paracrine TGF-β signaling in regulation of squamous differentiation of airway epithelial cells. We investigated the role of airway epithelial integrin αvβ6–mediated autocrine TGF-β in promoting the expression of a panel of 6 genes that were differentially expressed during serial passage and that include members of gene clusters on chromosome 1q21 known as the epidermal differentiation complex (EDC) (Table 1 and http://www.ncbi.nlm.nih.gov/geo/, series accession GSE7557; IVL, DSC2, SPRR1A, SPRR1B, SPRR3, S100A7) (42, 43). Neutralizing anti-β6 decreased the transcript expression of all 6 tested members of the EDC (Figure 7D). These results suggest that autocrine αvβ6–mediated activation of TGF-β plays an active role in promoting squamous differentiation.
We next investigated the role of αvβ8-dependent paracrine secretion of active TGF-β by airway fibroblasts in regulation of human bronchial epithelial cell β6 expression. In P0 human bronchial epithelial cells, β6 transcript expression was found to be TGF-β dependent (Figure 8A). To determine the paracrine role of αvβ8-mediated activation of TGF-β by airway fibroblasts in regulation of human bronchial epithelial cell β6 expression, P0 human bronchial epithelial cells were cocultured with airway fibroblasts, which had been transfected with control or β8 siRNA. The P0 human bronchial epithelial cell expression of the β6 transcript was significantly increased by coculture with control transfected airway fibroblasts compared with P0 human bronchial epithelial cells cultured alone (Figure 8A). The majority of this increase was due to TGF-β, since the increase could be largely blocked by neutralizing anti–TGF-β (Figure 8A). Furthermore, the increase in expression of the human bronchial epithelial cells’ β6 transcript was partially dependent on αvβ8-mediated activation of TGF-β by airway fibroblasts, since the majority of the increase in human bronchial epithelial cells’ β6 expression induced by coculture with airway fibroblasts could be blocked by transfection of fibroblasts with siRNA to β8 (Figure 8A). β6 surface expression was also increased when P0 human bronchial epithelial cells were cocultured with control siRNA–treated airway fibroblasts (Figure 8B). This increase was significantly less when P0 human bronchial epithelial cells were cocultured with β8 siRNA–treated airway fibroblasts (Figure 8B).
Fibroblast αvβ8-mediated activation of TGF-β contributes to β6 expression by adjacent human bronchial epithelial cells through a paracrine mechanism. (A) P0 human bronchial epithelial cells were cultured on filter inserts and were cultured alone (monoculture) or cocultured with control siRNA- or β8 siRNA–transfected airway fibroblasts in the bottom chamber treated with control antibody (control Ab) or neutralizing anti–TGF-β for 48 hours. Total human bronchial epithelial cell RNA was harvested, and β6 expression was determined by RT-PCR using primers to β6 or β-actin, as a control. Shown is a representative experiment of 3 showing similar results. (B) P0 human bronchial epithelial cells grown on filter inserts were similarly cocultured alone or with control siRNA (white bar) or β8 siRNA (black bar) transfected airway fibroblasts for 48 hours (n = 5). β6 surface expression was determined by flow cytometry using anti-β6. Shown is increase in surface expression relative to human bronchial epithelial cells in monoculture. Shown is SEM. *P < 0.05.
Increased β8 expression in small airway fibroblasts correlates with increasing severity of COPD and airway wall thickening. We used immunohistochemistry to evaluate the expression of β8 in the fibroblasts surrounding the small airways in a cohort of normal and COPD patients. We found that the β8 antibody strongly stained airway basal cells, as previously reported (44), as well as the subepithelial airway fibroblasts (Figure 9A). The intensity of β8 staining correlated significantly with increasing severity of disease, as classified by GOLD (Figure 9B), and with increasing airway wall thickness (Figure 9C). We next evaluated lung fibroblasts harvested from normal and COPD patients for β8 expression. Lung fibroblasts harvested from COPD patients expressed significantly more β8 and activated more TGF-β than fibroblasts from normal patients (Figure 9, D and E).
Expression of the integrin β8 is increased in small airway fibroblasts in COPD; its expression correlates with GOLD stage, airway wall thickness, and TGF-β activation. Human lung samples obtained from patients with COPD (n = 22) or from normal controls (n = 12) were evaluated for β8 expression by immunostaining (A–C), flow cytometry (D), and TGF-β bioassay (E). In A, a histologic section of a small airway with SM is depicted with strong β8 staining in the basal cells (arrowheads) and moderate staining in the adjacent subepithelial fibroblasts (arrows). Scale bar: 50 μm. (B) Average β8 staining intensity is shown for normal lung samples and samples from GOLD stage 1–3 patients based on the 0–3 grading scale (see Methods). *P < 0.05, **P < 0.01. (C) Wall thickness was approximated by measuring the area of the airway wall from the basement membrane (BM) to the adventitia/length of the BM, using the method of Hogg (5). Shown is the relationship between wall thickness and β8 staining intensity. (D and E) Fibroblasts were harvested from lung parenchyma from normal patients (n = 6) or patients with COPD (n = 5) and were (D) stained with anti-β8 and analyzed using flow cytometry or (E) cocultured with TGF-β reporter cells (TMLC) in the presence or absence of neutralizing anti-β8. In D, shown is mean fluorescence intensity ± SE. *P < 0.05. In E, TGF-β activation is expressed as relative to the total light units obtained with anti–TGF-β. *P < 0.05.
Association of SM with COPD was described nearly 30 years ago (7). However, a mechanistic connection between SM and COPD may have been overlooked due to the long-held assumption that SM functions solely as a benign protective cellular reaction to injury. We have used recent advances in genome-wide analysis and gene silencing to parse out the complex role that SM plays in amplifying pathologic interactions between airway epithelium and fibroblasts in the evolution of airway remodeling in COPD. We have provided evidence of bidirectional paracrine signaling, mediated by the integrins αvβ6 and αvβ8, effecting both epithelial and mesenchymal differentiation in the adult airway (Figure 10). As such, amplification of integrin-mediated activation of TGF-β, by way of SM, may play a key role in derangement of morphoregulatory molecules and subsequent spatiotemporal interactions required to maintain homeostasis of the epithelial-mesenchymal trophic unit.
Hypothetical model of SM in the pathogenesis of airway wall thickening in COPD. (a) The normal airway epithelium when exposed to noxious stimuli responds by increasing TGF-β production (12) and increasing TGF-β activation, which increases expression of the β6 integrin, a TGF-β responsive gene (31) contributing to (b) a phenotypic switch to SM, a TGF-β driven process (11). (c) Squamous metaplastic epithelial cells secrete increased IL-1β, which acts a paracrine factor with adjacent airway fibroblasts. (d) Airway fibroblasts respond to IL-1β by increasing β8 expression and αvβ8-mediated TGF-β activation. Increased TGF-β activation by airway fibroblasts causes (e) autocrine effects on the fibrogenic fibroblast phenotype by increasing Col I and αSMA and (f) paracrine effects on adjacent airway epithelium, which inhibits epithelial proliferation (10, 44, 66) and contributes to the increased expression of β6 by adjacent airway epithelial cells, forming a self-amplifying loop of TGF-β activation.
The SM that we observe in P3 human bronchial epithelial cells shares many similarities with SM in COPD. Thus, expression of IL-1β, basal, and suprabasal squamous epithelial markers, integrin subunits β6 and β8, and proliferation markers from our in vitro model mirror the immunohistochemical staining data of SM in human airways. These findings are consistent with the work of others suggesting that SM occurs through the increased recruitment of basal cells into an amplifying population of committed squamous lineage cells (29). This amplifying population occupies the suprabasal layer and expresses involucrin, keratin 6B, and keratin 14, which are known markers of actively proliferating suprabasal cells in normal squamous mucosa, SM either in the lung or other mucosal sites, and the epidermis at the edge of wounds (29, 30, 45–47).
During in vitro SM, the most highly induced gene, from an unbiased genome-wide analysis approach, was the proinflammatory gene IL-1β. IL-1β has been shown to be expressed in the skin in vivo and in keratinocytes in 2D culture (48, 49), where it may represent epidermal “activation” in response to epithelial injury and link innate immune responses to subsequent adaptive immune responses, ultimately promoting wound repair (50). Thus, the induction of IL-1β that occurs during SM of the airway epithelium may act as both an autocrine factor to influence gene expression to facilitate cell migration and wound closure and as a paracrine factor to recruit inflammatory cells and to induce matrix production and contractility of adjacent fibroblasts (51, 52). The basal, suprabasal, and superficial cells of SM in COPD all express increased IL-1β, suggesting that both increased luminal and basal secretion of IL-1β are provided by the squamous metaplastic epithelium. This increased IL-1β secreted by SM may be an important additional source of IL-1β, complementing the pool of IL-1β produced by immune effector cells.
We find that IL-1β secreted by metaplastic squamous airway epithelial cells promotes collagen expression by airway fibroblasts through increased fibroblast expression of αvβ8 and a subsequent increase in TGF-β activation. In contrast, in a study utilizing a coculture model of keratinocytes and dermal fibroblasts, myofibroblast differentiation was TGF-β dependent but was antagonized by IL-1β (52). The discrepancy between these 2 studies likely represents inherent cell type–specific differences between airway and dermal fibroblasts. For instance, we have found that unlike human airway fibroblasts, human dermal fibroblasts do not express αvβ8 (53). However, it is likely that there are other differences between airway epithelial cells and keratinocytes in the cofactors that they secrete that can modify fibroblast responses to IL-1β.
We, like others, have found that SM is an inevitable consequence of 2D but not air-liquid interface culture, indicating that caution must be exercised when interpreting the results of many of the studies that have been published using human bronchial epithelial cells in 2D culture, as they may represent squamous metaplastic cells bearing little similarity to normal airway epithelium. On the other hand, 2D human bronchial epithelial cell culture provides an excellent model of the important in vivo phenomenon of SM.
We have created a simplified coculture model of the epithelial-mesenchymal trophic unit to study the reciprocal interactions between airway epithelial cells and the adjacent fibroblasts. In vivo, these cell types are separated by a basement membrane, where movement of proteins may be physically impaired by pore size or interactions with matrix components. Thus, our model, which does not provide an intact basement membrane, may overestimate the importance of paracrine secretion of IL-1β and TGF-β in vivo. However, IL-1β and TGF-β are compact proteins that appear to move freely through basement membranes (54, 55), which increases the likelihood that the paracrine interactions that we observe in our coculture model are physiologically relevant.
In the epithelial-mesenchymal trophic unit, we propose an important role for integrin-mediated TGF-β activation in driving SM. However, blocking integrin-mediated TGF-β activation only delays and does not completely prevent squamous differentiation in our systems. This is expected since integrin-mediated TGF-β activation only accounts for approximately 50% of the total TGF-β activation by airway epithelial cells. This partial effect could be due to antibody efficacy or other integrin-independent mechanisms of activating TGF-β, such as matrix metalloproteases-2 and -9 (56), thrombospondin-1 (19), or plasmin (57). Finally, we have not defined the mechanism that initiates integrin-mediated TGF-β activation by airway epithelial cells. We speculate that since normal airway epithelial cells express relatively high levels of αvβ8 and low levels of the αvβ6 integrin, some environmental stimulus may activate the pathways involved in airway epithelial αvβ8–mediated activation of TGF-β, thus increasing TGF-β activation, which would increase β6 expression and initiate SM. Our previous data support this hypothesis. For instance, we have found that P0 fetal tracheal epithelial cells express αvβ8 but do not efficiently support αvβ8-mediated activation of TGF-β, which correlates with low expression of MT1-MMP (10). When fetal tracheal epithelial cells are stimulated with phorbol esters, MT1-MMP activity increases coincident with increasing αvβ8-mediated activation of TGF-β (10). Therefore, we speculate that environmental stimuli, such as tobacco smoke, may also increase αvβ8-mediated activation of TGF-β through a similar mechanism and thus initiate TGF-β–dependent SM.
Cell culture, antibodies, and reagents. Adult airways were collected from first through fourth order bronchi from lobectomy specimens from resections performed for primary lung cancer or from normal lungs not used for transplantation. Informed consent was obtained from all surgical participants as part of an approved ongoing research protocol by the University of California San Francisco Committee on Human Research, in full accordance with the declaration of Helsinki principles. Normal human bronchial epithelial cells were isolated as previously described (58). Freshly isolated adult human bronchial epithelial cells were plated onto rat-tail Col I–coated (10 μg/ml) dishes and incubated overnight; then the medium was changed to bronchial epithelial growth medium (BEGM) (Clonetics). Human bronchial epithelial cells were serially passaged to P6. For air-liquid interface culture, P0 airway epithelial cells were seeded onto human placental collagen–coated filters (Sigma-Aldrich; Costar, Corning), as previously described using 2% Ultraser G–containing (Invitrogen) medium (58). Cells were cultured until confluent (as indicated by the ability to resist fluid movement through the epithelial layer), and then the medium on top of the filter was removed. To induce SM of air-liquid interface cultures, the medium was changed to BEGM (Clonetics), and the cultures were harvested at 3 and 21 days after exchange of the medium. Airway fibroblasts were cultured from the airway tissues remaining after epithelial cell isolation by the explant technique (58) and used P1 to P4. The TGF-β reporter cell line, TMLC (gift of John Munger and Dan Rifkin, New York University, New York, New York, USA) were cultured as previously described (59).
Antibodies used were mouse anti-β8 (clones 14E5 and 37e1; ref. 20), rabbit anti-β8 (G17, Santa Cruz Biotechnology Inc.), anti-β3 (clone LM609, Chemicon), anti-β5 (clone P1F6, Chemicon), anti-β6 (10D5, ref. 60; B64B5, ref. 61), and mouse anti-involucrin, anti–keratin 6, anti–keratin 14, p63 (LabVision), rabbit anti–Ki-67 (Cell Marque Corp.), mouse anti–Col I (Southern Biotech), mouse anti-αSMA (Sigma-Aldrich), goat anti–IL-1β and blocking peptide (Santa Cruz Biotechnology Inc.), biotinylated affinity purified goat anti–IL-1β (R&D Systems), anti–pan–TGF-β, and mouse anti-HLA class I (1D11 and W6/32, ATCC). Recombinant active TGF-β1, IL-1β (R&D Systems), IL-1RA (Affinity BioReagents), the pan-metalloprotease inhibitor GM6001 (Ryss Lab), and Vitrogen (Cohesion) were purchased. Rat-tail collagen was isolated as previously described (62).
Plasmids, siRNA, and transfection. The β8, MT1-MMP, and control vectors were previously described (20, 63). The MT1-MMP, β8, and negative control siRNAs were purchased (Ambion Inc.), and transfection of primary cultured cells were performed using the Amaxa Nucleofector (Amaxa Biosystems), using matched optimized transfection kits for airway epithelial cells and fibroblasts.
Immunocytochemistry, immunohistochemistry, and flow cytometry. Immunocytochemistry, immunohistochemistry, cell cycle analysis and flow cytometry were performed as previously described (44). Senescence-associated β-gal (SA β-gal), a marker of cellular senescence (64), was performed using human bronchial epithelial cells (2 × 105) grown on 12-well culture plate according to the manufacturer’s instructions (β-galactosidase staining kit; BioVision Research Products).
Airway morphometry. Leftover human lung samples from pulmonary lobectomies or pneumonectomies performed at the San Francisco General Hospital or Moffit-Long Hospital, University of California San Francisco, for lung cancer, were gathered during the study period (from 2003 through 2006). Exclusion criteria included infection, prior radiation, or chemotherapy. Control lung tissues were obtained from donor lungs not utilized for lung transplantation, usually for reasons of size mismatching.
Microtome sections from 34 (22 COPD and 12 normal) lung samples were immunostained for involucrin or β8. The slides were coded and blinded prior to pathologic assessment. Airway diameter was determined using a stage micrometer, and airways less than 2 mm in diameter were evaluated (mean 5.8 ± 5.3 airways/case). Each small airway was digitally imaged at 200× magnification (QCapture, v. 2.68.2). Digital images were assessed for β8 immunostaining based on a 0–3 scale, with 0 being absent staining; grade 1, 0–10%; grade 2, 11–30%; grade 3, >30% of airway cells or subepithelial fibroblasts with positive membrane and cytoplasmic staining. Involucrin immunostaining was also graded on a 0–3 scale, with 0 being absent staining; grade 1, 0–10%; grade 2, 11–20%; grade 3, >20% cytoplasmic staining of superficial “squamoid” cells. Measurements of wall thickness were performed using the method of Hogg (5), which expresses wall thickness as a function of area of the airway wall/basement membrane length using image analysis software (ImageJ, v. 1.36b).
After immunohistochemical assessment, the clinical records from each patient were retrieved and the degree of pulmonary disability (stages 1 to 4, with 4 being the worst) was determined using GOLD criteria. Preoperative pulmonary function tests (PFTs) were available for 18 of 20 patients undergoing surgery. The number of patients in each stage with PFTs available were as follows: stage 1, n = 3; stage 2, n = 11; stage 3, n = 4; and stage 4, n = 0.
RNA isolation, polymerase chain reaction, and microarray analysis. RNA isolation and RT-PCR were performed as previously described (20). Real-time PCR was performed using the SYBR green method, as described (65). Primer sequences are available in supplemental data (Supplemental Table 4). Microarray methodology is available in supplemental data.
Immunoprecipitation analysis, Western blotting, zymography, and TGF-β bioassay. Immunoprecipitations and SDS-PAGE were performed as previously described (10, 63). Western blotting of conditioned medium of coculture system was performed as described with minor modification (10). The TGF-β bioassays and zymography to determine MT1-MMP activity were performed as previously described (10, 20).
Cytokine array and IL-1β ELISA. Airway epithelial cells (3 × 106) were cultured in 10-cm collagen-coated tissue culture plates for 12–16 hours, washed 2 times with PBS, then incubated in serum-free DMEM for 72 hours. Cytokines in conditioned medium were detected with Cartesian Array Human Cytokine Set 1 from BioSource International (Invitrogen) following the manufacturer’s instructions. IL-1β was measured in conditioned medium with an IL-1β Quantikine ELISA kit (R&D Systems).
Coculture model of the epithelial-mesenchymal trophic unit. Airway epithelial cells (2 × 105/well) were seeded on vitrogen-coated (10 μg/ml coating concentration) culture inserts (1 mm pore size; BD Biosciences) in a 24-well plate in BEGM (Clonetics) and cultured until confluent. Airway fibroblasts transfected with control or β8 siRNA (2.5 μg/transfection) were cultured for 12–16 hours on 24-well (2 × 105/well) tissue-coated plate (BD Biosciences) in fibroblast growth medium. For the coculture experiments, the culture inserts containing the airway epithelial cells were placed into wells containing airway fibroblasts, and medium in both the upper and lower chambers were changed to DMEM without FCS in the presence or absence of control antibody, anti–TGF-β antibody (1D11), anti–β6 integrin antibody (10D5), anti–β8 integrin antibody (37E1), or IL-1RA. After 48 or 72 hours coculture, integrin expression levels in airway epithelial cells were analyzed by FACS and RT-PCR. Col I gene expression in fibroblasts was evaluated by RT-PCR or by Western blotting of conditioned medium.
Statistics. Stepwise regression analysis with correction for clustering was used to compare β8 staining intensity to airway wall thickness. Student’s t test was used for comparison of 2 data sets, analysis of variance for multiple data sets. Tukey’s or Dunn’s test were used for parametric and nonparametric data, respectively, to find where the difference lay. Significance was defined as P < 0.05. Statistical software used was Prism v.3cx (GraphPad Software Inc.) and Stata v.9 (StataCorp LP).
We would like to thank Charles McCullough (UCSF Division of Biostatistics) for biostatistical assistance and Rebecca Barbeau, Alicia Goodwin, and Alana Morris for technical assistance. This work was supported by NIH grants HL63993 and HL70622, the UCSF Academic Senate (to S. Nishimura), NIH grants HL72301 (to D. Erle), HL53949, HL083950, HL64353, AI024674 (to D. Sheppard), CA95671 (to V.C. Broaddus), and DK72517 and a grant from the Cystic Fibrosis Foundation (to W. Finkbeiner). We thank UCSF and Sandler Asthma Basic Research Center and Amha Atakilit for providing reagents.
Address correspondence to: Stephen L. Nishimura, San Francisco General Hospital, Building 3, Room 211, 1001 Potrero Avenue, San Francisco, California 94110, USA. Phone: (415) 206-5906; Fax: (415) 206-5988; E-mail: stephen.nishimura@ucsf.edu.
Nonstandard abbreviations used: BEGM, bronchial epithelial growth medium; Col I, type I collagen; COPD, chronic obstructive pulmonary disease; EDC, epidermal differentiation complex; GOLD, Global Initiative for Obstructive Lung Disease; IL-1RA, IL-1 receptor antagonist; LAP, latency-associated peptide; MT1-MMP, membrane type I–MMP; P0, initial passage; P2, second passage; SM, squamous metaplasia.
Conflict of interest: The authors have declared that no conflict of interest exists.
Reference information: J. Clin. Invest.117:3551–3562 (2007). doi:10.1172/JCI32526